Drug Trial Radar · NCT07235176
Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jan 16, 2026
Primary completion
Nov 2, 2028
Study completion Dec 30, 2031
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, open label, phase Ib/II clinical trial aimed at evaluating the safety, preliminary efficacy characteristic and PK characteristics of QLS1304 in combined with endocrine therapy in ER+/HER2- breast cancer patients. This study was divided into two stages: combo dose escalation and dose expansion.
Conditions
- Advanced ER+/HER2- Breast Cancer
Interventions
QLS1304 tablet+Fulvestrant or QLC1401Drug
QLS1304 combined with endocrine therapy
QLS1304 tablet+Fulvestrant,AI or QLC1401+CDK4/6iDrug
QLS1304 combined with endocrine therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase II Dose (RP2D) of QLS1304 in combo therapyTime frame: through study completion,an average of 2 years
- objective response rate(ORR)Time frame: through study completion,an average of 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Cancer Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.